The function of PCSK9 in doxorubicin-induced cardiotoxicity and its underlying mechanism
Abstract Doxorubicin (DOX) is an anthracycline class of chemotherapy drug, the application of which is limited due to its cardiotoxic effects. Recombinant Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), is a serine protease pivotal in lipid metabolism and has a profound correlation with the o...
Saved in:
| Main Authors: | Shuai Shi, Zhihui Qin, Chang Liu, Yanru Zhao, Xiaopeng Bai, Chaoyu Sun, Xu Li, Wanting Cong, Xinyue Yuan, Lixiu Sun, Bingchen Liu, Xueqi Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-03419-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of pimobendan on cytokine levels in doxorubicin-induced cardiotoxicity
by: Burak Dik, et al. -
Investigate if Metoprolol and Troxerutin Could Prevent Cardiotoxicity Mitigated by Doxorubicin
by: Fouad Zeidan Hamzah, et al.
Published: (2025-07-01) -
Micellar Nanoformulation of Berberine to Mitigate Doxorubicin-induced Cardiotoxicity: A Cell-line Study
by: Noora Alyasari, et al.
Published: (2023-12-01) -
Pathophysiology of Doxorubicin-Mediated Cardiotoxicity
by: Roberto Arrigoni, et al.
Published: (2025-04-01) -
PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01)